Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
K562
100%
Human Leukemia Cells
100%
GTI-2040
100%
Chemical Modulation
100%
Ribonucleotide Reductase Inhibitor
100%
Triphosphate
36%
DNTP Pools
36%
Ara-C
27%
Protein Level
18%
Ribonucleotide Reductase
18%
Electroporation
9%
Quantitative PCR
9%
Acute Myeloid Leukemia
9%
Cytarabine
9%
Drug Treatment
9%
Cytotoxicity
9%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
9%
Antisense
9%
Combination Treatment
9%
Western Blot
9%
Synergistic Cytotoxicity
9%
Cytotoxic Effect
9%
Ligation
9%
K562 Cells
9%
Nucleoside Triphosphates
9%
Intracellular Level
9%
Non-radioactive
9%
Tetrazolium
9%
Deoxynucleotides
9%
Experimental Support
9%
HPLC-UV
9%
Ribonucleotide Reductase M2
9%
Modulation Effect
9%
MS Method
9%
Inner Salt
9%
Phase Current
9%
Dose-dependent
9%
De-novo Synthesis
9%
Biochemistry, Genetics and Molecular Biology
Ribonucleotide Reductase Inhibitor
100%
Cytarabine
100%
Cytotoxicity
33%
Ribonucleotide Reductase
33%
Messenger RNA
22%
Western Blot
11%
Antisense
11%
Electroporation
11%
Enzyme
11%
Real-Time Polymerase Chain Reaction
11%
Myeloid
11%
Tandem Mass Spectrometry
11%
High-Performance Liquid Chromatography
11%
K562 Cells
11%
Liquid Chromatography-Mass Spectrometry
11%
Arabinofuranosylcytosine Triphosphate
11%
Nucleoside Triphosphate
11%
Deoxyribonucleotide
11%
Drug Therapy
11%
Nucleotide
11%